Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019

Date: January 26, 2015
Pages: 211
Price:
US$ 4,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V1EF8A3C425EN
Leaflet:

Download PDF Leaflet

Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019
The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. The global vaccines market is categorized on the basis of type, technology, disease indication, end user, and geography. The preventive vaccines segment is expected to register the highest growth rate in the vaccines market, by type, during the forecast period. Its favorable growth is attributed to the rising prevalence of diseases and increasing number of government initiatives taken for immunization programs worldwide.

Major factors contributing to growth of the vaccines market include rising prevalence of diseases, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in November 2014, the U.K. government granted $2 billion (£1.32 billion) to GAVI for the improvement of immunization programs in poor countries. The emerging markets of the Asian region have opened an array of opportunities for the vaccines market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of this market.

Apart from the comprehensive geographical and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by the industry players over the last three years. In addition, the company profiles comprise the basic views on the key players in the vaccines market and the product portfolios, developments, and strategies adopted by the market players to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of the future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on product portfolios of the top players in the vaccines market. The report analyzes the vaccines market by type, technology, disease indication, end users, and geography
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccines market
  • Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the vaccines market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various vaccines across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the vaccines market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
2.4 KEY DATA FROM SECONDARY SOURCES
2.5 KEY DATA FROM PRIMARY SOURCES
2.6 KEY INDUSTRY INSIGHTS
2.7 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 VACCINES MARKET HAS HIGH GROWTH POTENTIAL
4.2 VACCINES MARKET, BY TYPE
4.3 VACCINES MARKET, BY REGION
4.4 VACCINES MARKET, BY DISEASE INDICATION
4.5 VACCINES MARKET, BY END USER
4.6 LIFECYCLE ANALYSIS, BY REGION

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
  5.2.1 VACCINES MARKET, BY TECHNOLOGY
  5.2.2 VACCINES MARKET, BY TYPE
  5.2.3 VACCINES MARKET, BY DISEASE INDICATION
  5.2.4 VACCINES MARKET, BY END USER
  5.2.5 VACCINES MARKET, BY REGION
5.3 MARKET DYNAMICS
  5.3.1 DRIVERS
    5.3.1.1 High prevalence of diseases
    5.3.1.2 Rising government and nongovernment funding for vaccine development
    5.3.1.3 Increasing investments by companies
    5.3.1.4 Technological advancements
  5.3.2 RESTRAINTS
    5.3.2.1 Huge capital investments
    5.3.2.2 Stringent regulatory procedures
  5.3.3 OPPORTUNITIES
    5.3.3.1 High growth prospects in emerging markets
    5.3.3.2 Therapeutic vaccines
    5.3.3.3 Adjuvant vaccines
  5.3.4 CHALLENGES
    5.3.4.1 Inadequate access to vaccines
    5.3.4.2 Vaccine pricing
  5.3.5 BURNING ISSUES
    5.3.5.1 Failure of vaccines

6 INDUSTRY INSIGHTS

6.1 PORTER’S FIVE FORCES ANALYSIS
  6.1.1 THREAT FROM NEW ENTRANTS
  6.1.2 BARGAINING POWER OF SUPPLIERS
  6.1.3 BARGAINING POWER OF BUYERS
  6.1.4 INTENSITY OF COMPETITIVE RIVALRY
  6.1.5 THREAT OF SUBSTITUTES
6.2 VALUE CHAIN ANALYSIS
6.3 SUPPLY CHAIN ANALYSIS
6.4 TECHNOLOGY TRENDS FOR ADJUVANTS
  6.4.1 DRIVERS
    6.4.1.1 Increasing Use of Adjuvants in Vaccine-preventable Diseases
    6.4.1.2 Rising Government Investments
  6.4.2 RESTRAINS
    6.4.2.1 High Cost of Research
    6.4.2.2 Regulatory Hurdles
  6.4.3 OPPORTUNITIES
    6.4.3.1 Combined Adjuvants
    6.4.3.2 Vaccines for Young Children
    6.4.3.3 Pandemic Diseases
  6.4.4 CHALLENGES
    6.4.4.1 Identification of Adjuvants
    6.4.4.2 Technological Limitations
  6.4.5 TRENDS
    6.4.5.1 Collaborations
    6.4.5.2 New Adjuvant Technologies
6.5 INVESTMENT ANALYSIS
6.6 REGULATORY LANDSCAPE
  6.6.1 NORTH AMERICA
  6.6.2 EUROPE
  6.6.3 ASIA
  6.6.4 ROW
6.7 PATENT ANALYSIS
6.8 KEY PIPELINE PRODUCTS
6.9 STRATEGIC BENCHMARKING

7 VACCINES MARKET, BY TECHNOLOGY

7.1 INTRODUCTION
7.2 SUBUNIT VACCINES
7.3 LIVE ATTENUATED VACCINES
7.4 CONJUGATE VACCINES
7.5 INACTIVATED VACCINES
7.6 RECOMBINANT VECTOR VACCINES
7.7 TOXOID VACCINES
7.8 SYNTHETIC VACCINES
7.9 DENDRITIC CELL VACCINES

8 VACCINES MARKET, BY TYPE

8.1 INTRODUCTION
8.2 PREVENTIVE VACCINES
8.3 THERAPEUTIC VACCINES

9 VACCINES MARKET, BY DISEASE INDICATION

9.1 INTRODUCTION
9.2 INFECTIOUS DISEASES
  9.2.1 PNEUMOCOCCAL
  9.2.2 INFLUENZA
  9.2.3 DTP
  9.2.4 HEPATITIS
  9.2.5 ROTAVIRUS
  9.2.6 VARICELLA
  9.2.7 MENINGOCOCCAL
  9.2.8 POLIO
  9.2.9 MMR
  9.2.10 OTHERS
9.3 CANCER
  9.3.1 CERVICAL CANCER
  9.3.2 OTHER CANCERS
9.4 ALLERGIES

10 VACCINES MARKET, BY END USER

10.1 INTRODUCTION
10.2 PEDIATRICS
10.3 ADULTS

11 GLOBAL VACCINES MARKET, BY REGION

11.1 INTRODUCTION
11.2 NORTH AMERICA
  11.2.1 U.S.
  11.2.2 CANADA
11.3 EUROPE
  11.3.1 GERMANY
  11.3.2 FRANCE
  11.3.3 U.K.
  11.3.4 ITALY
  11.3.5 SPAIN
  11.3.6 REST OF EUROPE (ROE)
11.4 ASIA
  11.4.1 JAPAN
  11.4.2 CHINA
  11.4.3 INDIA
  11.4.4 REST OF ASIA (ROA)
11.5 REST OF THE WORLD (ROW)

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS
12.3 COMPETITIVE SITUATION AND TRENDS
  12.3.1 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS
  12.3.2 REGULATORY APPROVALS
  12.3.3 ACQUISITIONS
  12.3.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

13.1 INTRODUCTION
13.2 GLAXOSMITHKLINE, PLC.
13.3 MERCK & CO., INC.
13.4 SANOFI PASTEUR
13.5 PFIZER, INC.
13.6 NOVARTIS AG
13.7 BAVARIAN NORDIC
13.8 CSL LIMITED
13.9 EMERGENT BIOSOLUTIONS, INC.
13.10 JOHNSON & JOHNSON
13.11 MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA) (Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.)

14 APPENDIX

14.1 RECENT DEVELOPMENTS
  14.1.1 GLAXOSMITHKLINE, PLC.
  14.1.2 SANOFI PASTEUR
  14.1.3 NOVARTIS AG
  14.1.4 EMERGENT BIOSOLUTIONS INC.
14.2 INSIGHTS FROM INDUSTRY EXPERTS
14.3 DISCUSSION GUIDE
14.4 AVAILABLE CUSTOMIZATIONS
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.6 RELATED REPORTS

LIST OF FIGURES

Figure 1 VACCINES MARKET, BY TECHNOLOGY
Figure 2 RESEARCH METHODOLOGY
Figure 1 TOP-DOWN APPROACH
Figure 2 BOTTOM-UP APPROACH
Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 DATA TRIANGULATION METHODOLOGY
Figure 5 VACCINE TECHNOLOGY MARKET SNAPSHOT (2014 VS. 2019): SUBUNIT VACCINES TO GROW AT HIGHEST CAGR
Figure 6 PREVENTIVE VACCINES TO DOMINATE THE VACCINES MARKET
Figure 7 PEDIATRIC SEGMENT WILL BE THE LARGEST END-USER SEGMENT IN THE VACCINES MARKET
Figure 8 NORTH AMERICA TO HOLD LARGEST SHARE IN THE GLOBAL VACCINES MARKET
Figure 9 HIGH PREVALENCE OF DISEASES TO DRIVE MARKET GROWTH
Figure 10 PREVENTIVE VACCINES SEGMENT HELD THE LARGEST SHARE IN VACCINES MARKET, BY TYPE
Figure 11 U.S. COMMANDS ONE-THIRD OF THE MARKET
Figure 12 INFECTIOUS DISEASES SEGMENT TO WITNESS SIGNIFICANT GROWTH IN EMERGING ECONOMIES
Figure 13 PEDIATRICS SEGMENT WILL CONTINUE TO LEAD THE VACCINES END-USERS MARKET DURING THE FORECAST PERIOD
Figure 14 ASIA TO WITNESS HIGH GROWTH RATE IN THE VACCINES MARKET DURING FORECAST PERIOD
Figure 15 VACCINES MARKET SEGMENTATION: BY TECHNOLOGY
Figure 16 VACCINES MARKET SEGMENTATION: BY TYPE
Figure 17 VACCINES MARKET SEGMENTATION: BY DISEASE INDICATION
Figure 18 VACCINES MARKET SEGMENTATION: BY END USER
Figure 19 VACCINES MARKET SEGMENTATION: BY REGION
Figure 20 INCREASING GOVERNMENT SUPPORT FOR PANDEMIC THREATS LIKELY TO FUEL GROWTH OF VACCINES MARKET
Figure 21 PORTER’S FIVE FORCES ANALYSIS
Figure 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE DEVELOPMENT AND MANUFACTURING PHASES
Figure 23 SUPPLY CHAIN ANALYSIS
Figure 24 COLD CHAIN MANAGEMENT
Figure 25 FDA-APPROVED VACCINE ADJUVANTS
Figure 26 LICENSED VACCINES CONTAINING ADJUVANTS
Figure 27 EXAMPLES OF VACCINE ADJUVANTS IN CLINICAL TRIALS
Figure 28 INVESTORS PLAY AN IMPORTANT ROLE IN THE VACCINES MARKET
Figure 29 VACCINE RESEARCH FUNDING, BY TYPE OF INVESTOR
Figure 30 U.S. GOVERNMENT AGENCIES HELD LARGEST SHARE OF THE HIV R&D FUNDING IN 2013
Figure 31 REGULATORY APPROVAL PROCESS FOR VACCINES
Figure 32 NORTH AMERICA ACCOUNTED FOR THE LARGEST NUMBER OF PATENT FILINGS IN 2012
Figure 33 THE U.S. ACCOUNTED FOR LARGEST NUMBER OF PATENT FILINGS ACROSS THE GLOBE (2012)
Figure 34 STRATEGIC BENCHMARKING: GLAXOSMITHKLINE, PLC. LARGELY ADOPTED INORGANIC GROWTH STRATEGIES FOR ENHANCING PRODUCT OFFERINGS
Figure 35 SUBUNIT VACCINES SEGMENT TO GROW AT HIGHEST CAGR IN FORECAST PERIOD
Figure 36 NORTH AMERICA TO DOMINATE THE INACTIVATED VACCINES MARKET FROM 2014 TO 2019
Figure 37 TOXOID VACCINES MARKET IN ASIA WILL GROW AT HIGHEST CAGR FROM 2014 TO 2019
Figure 38 PREVENTIVE VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET FROM 2014 TO 2019
Figure 39 ASIA TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019
Figure 40 INFECTIOUS DISEASES SEGMENT TO DOMINATE THE VACCINES MARKET FROM 2014 TO 2019
Figure 41 THE PEDIATRICS END-USER SEGMENT WILL DRIVE THE VACCINES MARKET DURING THE FORECAST PERIOD
Figure 42 GEOGRAPHIC SNAPSHOT (2014): EMERGING MARKETS HOLD GROWTH OPPORTUNITIES
Figure 43 GEOGRAPHIC BENCHMARKING FOR VACCINES TECHNOLOGY MARKET
Figure 44 MARKET GROWTH WILL BE DRIVEN BY INCREASING R&D ACTIVITIES FOR DEVELOPMENT OF VACCINES
Figure 45 INFECTIOUS DISEASES SEGMENT WILL CONTINUE TO DRIVE THE VACCINES MARKET
Figure 46 GERMANY WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN EUROPE
Figure 47 GERMAN VACCINES MARKET TO GROW AT THE HIGHEST CAGR IN EUROPE
Figure 48 VACCINES MARKET IN ASIA GROW AT THE HIGHEST CAGR
Figure 49 INDIAN VACCINES MARKET WILL HAVE HIGH GROWTH POTENTIAL
Figure 50 PREVENTIVE VACCINES WILL LEAD THE ROW VACCINES MARKET IN 2019
Figure 51 MAJOR PLAYERS SIGNED AGREEMENTS TO ENHANCE THEIR MARKET POSITIONS IN THE VACCINES MARKET
Figure 52 VACCINES MARKET SHARE, BY KEY PLAYER, 2013
Figure 53 BATTLE FOR MARKET SHARE: AGREEMENTS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS
Figure 54 PRODUCT BENCHMARKING FOR TOP 5 MARKET PLAYERS
Figure 55 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT
Figure 56 MERCK & CO., INC.: COMPANY SNAPSHOT
Figure 57 SANOFI PASTEUR: COMPANY SNAPSHOT
Figure 58 PFIZER INC.: COMPANY SNAPSHOT
Figure 59 NOVARTIS AG: COMPANY SNAPSHOT
Figure 60 BAVARIAN NORDIC: COMPANY SNAPSHOT
Figure 61 CSL LIMITED: COMPANY SNAPSHOT
Figure 62 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
Figure 63 JOHNSON & JOHNSON: COMPANY SNAPSHOT
Figure 64 ASTRAZENECA: COMPANY SNAPSHOT

The global vaccine technology market is anticipated to reach around $84 billion by 2022, growing at a CAGR of 11.36%. The vaccine market is divided by technology class (Live/Attenuated, Toxoid, Conjugate, Sub-Unit, Recombinant Vector, DNA, Synthetic, and Dentritic Vaccines), types (Preventive and Therapeutic), end users (Pediatric and Adult), disease indication (Infectious Diseases, Cancer, Allergies, and Others – Diabetes, Cardiovascular Diseases), and geography (North America, Europe, Asia, and Rest of the World). Furthermore, each technology class, type, end user, and disease indication segment is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned disease indication segments, infectious disease vaccines are the largest revenue segment; however, cancer vaccines will be the fastest-growing segment with the highest CAGR.

The potential growth of the market is attributed towards therapeutic vaccines, allergy vaccines, and emerging-disease vaccines. Improved understanding of immunology, new technological breakthroughs in the development of a new class of vaccines, namely, recombinant vector vaccines, DNA vaccines, and dendritic vaccines coupled with excellent distribution channels are propelling the growth of this market. Furthermore, a large population base in emerging economies and a high prevalence of diseases is driving the market, which is expected to remain consistent in the coming years. Largely popular as the biological preparation exclusively for the prevention of diseases, vaccines are now emerging as therapeutic agents for improving the immune system. This is adding a new dimension to the vaccine industry, opening doors for the treatment of various ailments, especially cancer, cardiovascular disease, diabetes, and smoke cessation. These opportunities have also paved the way for the entry of new companies and for the development of newer technology platforms. Furthermore, new emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are paving the way for the development of new effective vaccines capable of addressing current and emerging infectious diseases and cancers.

North America (42%) is a significant contributor, followed by Europe (36%), due to the highly structured healthcare reimbursement policies and the high purchasing power of costly vaccines. The new markets for vaccine are expected to grow at a vigorous pace in emerging economies such as China, India, and other regions in Asia-Pacific and untapped markets in Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

The key players in this market are Novartis (Switzerland), Glaxo Smithkline (U.K.), Merck (U.S.), Sanofi (France), Pfizer (U.S.), Antigen Express, Inc. (U.S.), Aduro Biotech (U.S.), Genticel (France), Biondvax (Israel), Immune Targeting Systems (U.K.), Prokarium (U.K.), Immunobiology Ltd. (U.K.), Liquidia Technologies (U.S.), Alphavax (U.S.), and Bavarian Nordic (Denmark).

The material was prepared in August, 2013.

LIST OF TABLES

Table 1 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH OF VACCINES
Table 2 HUGE CAPITAL INVESTMENT TO LIMIT THE MARKET GROWTH OF VACCINES
Table 3 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH OF VACCINES
Table 4 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH OF VACCINES
Table 5 NATIONAL INSTITUTES OF HEALTH (NIH) FUNDING FOR VACCINE DEVELOPMENT, 2011–2013 ($MILLION)
Table 6 REGULATORY AUTHORITIES IN EUROPE
Table 7 REGULATORY AUTHORITIES IN ASIA
Table 8 KEY PIPELINE VACCINES
Table 9 VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 10 SUBUNIT VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 11 NORTH AMERICA: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 12 EUROPE: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 13 ASIA: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 14 LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 15 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 16 EUROPE: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 17 ASIA: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 18 CONJUGATE VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 19 NORTH AMERICA: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 20 EUROPE: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 21 ASIA: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 22 INACTIVATED VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 23 NORTH AMERICA: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 24 EUROPE: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 25 ASIA: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 26 RECOMBINANT VECTOR VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 27 NORTH AMERICA: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 28 EUROPE: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 29 ASIA: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 30 TOXOID VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 31 NORTH AMERICA: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 32 EUROPE: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 33 ASIA: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 34 SYNTHETIC VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 35 NORTH AMERICA: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 36 EUROPE: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 37 ASIA: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 38 DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION)
Table 39 NORTH AMERICA: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 40 EUROPE: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 41 ASIA: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION)
Table 42 VACCINES MARKET SIZE, BY TYPE, 2012–2019 ($MILLION)
Table 43 PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
Table 44 NORTH AMERICA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 45 EUROPE: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 46 ASIA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 47 THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
Table 48 NORTH AMERICA: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 49 EUROPE: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 50 ASIA: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 51 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012–2019 ($MILLION)
Table 52 VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION, 2012-2019 ($MILLION)
Table 53 NORTH AMERICA: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2012–2019 ($MILLION)
Table 54 EUROPE: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2012–2019 ($MILLION)
Table 55 ASIA: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2012-2019 ($MILLION)
Table 56 INFECTIOUS DISEASES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 57 VACCINES MARKET SIZE FOR CANCER, BY REGION, 2012–2019 ($MILLION)
Table 58 NORTH AMERICA: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY, 2012–2019 ($MILLION)
Table 59 EUROPE: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY, 2012–2019 ($MILLION)
Table 60 ASIA: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY, 2012–2019 ($MILLION)
Table 61 CANCER VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 62 VACCINES MARKET SIZE FOR ALLERGIES, BY REGION, 2012–2019 ($MILLION)
Table 63 NORTH AMERICA: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY, 2012–2019 ($MILLION)
Table 64 EUROPE: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY, 2012–2019 ($MILLION)
Table 65 ASIA: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY, 2012–2019 ($MILLION)
Table 66 VACCINES MARKET SIZE, BY END USER, 2012–2019 ($MILLION)
Table 67 VACCINES MARKET SIZE FOR PEDIATRICS, BY REGION, 2012–2019 ($MILLION)
Table 68 NORTH AMERICA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2012–2019 ($MILLION)
Table 69 EUROPE: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2012–2019 ($MILLION)
Table 70 ASIA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY, 2012–2019 ($MILLION)
Table 71 VACCINES MARKET SIZE FOR ADULTS, BY REGION, 2012–2019 ($MILLION)
Table 72 NORTH AMERICA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2012–2019 ($MILLION)
Table 73 EUROPE: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2012–2019 ($MILLION)
Table 74 ASIA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2012–2019 ($MILLION)
Table 75 VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION)
Table 76 NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 77 EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 78 ASIA: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION)
Table 79 NORTH AMERICA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 80 NORTH AMERICA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 81 NORTH AMERICA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 82 NORTH AMERICA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 83 U.S.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 84 U.S.: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 85 U.S.: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 86 U.S.: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 87 CANADA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 88 CANADA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 89 CANADA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 90 CANADA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 91 EUROPE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 92 EUROPE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 93 EUROPE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 94 EUROPE: VACCINES MARKET SIZE, BY END USERS, 2012-2019 ($MILLION)
Table 95 GERMANY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 96 GERMANY: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 97 GERMANY: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 98 GERMANY: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 99 FRANCE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 100 FRANCE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 101 FRANCE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 102 FRANCE: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 103 U.K.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 104 U.K.: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 105 U.K.: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 106 U.K.: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 107 ITALY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 108 ITALY: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 109 ITALY: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 110 ITALY: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 111 SPAIN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 112 SPAIN: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 113 SPAIN: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 114 SPAIN: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 115 ROE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 116 ROE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 117 ROE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 118 ROE: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 119 ASIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 120 ASIA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 121 ASIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 122 ASIA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 123 JAPAN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 124 JAPAN: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 125 JAPAN: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 126 JAPAN: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 127 CHINA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 128 CHINA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 129 CHINA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 130 CHINA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 131 INDIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 132 INDIA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 133 INDIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 134 INDIA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 135 ROA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 136 ROA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 137 ROA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 138 ROA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 139 ROW: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION)
Table 140 ROW: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION)
Table 141 ROW: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION)
Table 142 ROW: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION)
Table 143 RECENT AGREEMENTS AND COLLABORATIONS
Table 144 RECENT REGULATORY APPROVALS
Table 145 RECENT ACQUISITIONS
Table 146 RECENT OTHER DEVELOPMENTS
Table 147 EXCHANGE RATES (UTILIZED FOR CONVERSION OF GBP TO USD)
Table 148 EXCHANGE RATES (UTILIZED FOR CONVERSION OF EURO TO USD)
Table 149 EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF DKK TO USD)



Ask Your Question

Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: